BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy BCDA?
Source: Newsfilter
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCDA
Wall Street analysts forecast BCDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.170
Low
6.00
Averages
15.50
High
25.00
Current: 1.170
Low
6.00
Averages
15.50
High
25.00
No data
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy
- Clinical Consultation Progress: BioCardia has completed its third preliminary clinical consultation with Japan's PMDA, preparing for formal discussions on the CardiAMP therapy for heart failure, which could pave the way for new treatment options in the Japanese market.
- Efficacy Data Support: Data from three clinical trials indicate that CardiAMP therapy shows positive outcomes in improving survival rates and reducing major adverse cardiovascular events, highlighting its potential value in treating heart failure patients.
- Innovative Treatment Mechanism: The CardiAMP cell therapy utilizes the patient's own bone marrow cells delivered via a minimally invasive catheter procedure to repair microvascular dysfunction, offering a new therapeutic option for ischemic heart failure patients.
- Clear Regulatory Pathway: The PMDA has indicated that BioCardia can advance to formal clinical consultation, and if the data sufficiently supports safety and efficacy, it will facilitate the company's application for regulatory approval in Japan, further driving its expansion in the Asia-Pacific market.
See More
BioCardia Elects Marvin Slosman to Board of Directors
- New Board Appointment: BioCardia announced the election of Marvin Slosman to its Board of Directors effective December 2, 2025, bringing deep expertise in interventional cardiology that is expected to drive innovation and market expansion in cardiovascular disease treatment.
- Rich Leadership Experience: Slosman, who previously served as CEO of InspireMD and held senior commercial leadership roles at Johnson & Johnson, GE Healthcare, and Baxter International, brings extensive market development and product commercialization experience that will aid BioCardia's strategic growth.
- Gratitude to Former Director: BioCardia expressed appreciation for departing board member Richard Krasno, who provided guidance during key milestones, particularly in the FDA approval of the CardiAMP cell therapy and the Morph DNA product.
- Strategic Company Development: The appointment of Slosman is expected to significantly support BioCardia's clinical value creation and global market expansion, further advancing the company's innovative solutions for treating cardiovascular and pulmonary diseases.
See More
BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality
New Appointment: BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, bringing over 25 years of experience in quality management and regulatory affairs from various companies in the healthcare sector.
Previous Experience: Shahab's prior roles include Vice President of Quality and Regulatory at Welldoc, Senior Director at Intuity Medical, and Director at Moximed, showcasing a strong background in product quality management across multiple medical device categories.
CEO's Statement: Peter Altman, CEO of BioCardia, expressed confidence in Shahab's expertise, stating that his leadership and experience will enhance the company's ability to commercialize investigational products.
Company Overview: BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with ongoing development of clinical-stage product candidates and innovative biotherapeutic delivery platforms.
See More
BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations
Earnings Performance: BioCardia, Inc. reported a loss of $1.48 million for the third quarter, an improvement from a loss of $1.74 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.24, compared to -$0.61 in the previous year, beating analysts' expectations of -$0.25 per share.
See More
BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy
- Clinical Consultation Progress: BioCardia has completed its third preliminary clinical consultation with Japan's PMDA, preparing for formal discussions on the CardiAMP therapy for heart failure, which could pave the way for new treatment options in the Japanese market.
- Efficacy Data Support: Data from three clinical trials indicate that CardiAMP therapy shows positive outcomes in improving survival rates and reducing major adverse cardiovascular events, highlighting its potential value in treating heart failure patients.
- Innovative Treatment Mechanism: The CardiAMP cell therapy utilizes the patient's own bone marrow cells delivered via a minimally invasive catheter procedure to repair microvascular dysfunction, offering a new therapeutic option for ischemic heart failure patients.
- Clear Regulatory Pathway: The PMDA has indicated that BioCardia can advance to formal clinical consultation, and if the data sufficiently supports safety and efficacy, it will facilitate the company's application for regulatory approval in Japan, further driving its expansion in the Asia-Pacific market.
See More
BioCardia Elects Marvin Slosman to Board of Directors
- New Board Appointment: BioCardia announced the election of Marvin Slosman to its Board of Directors effective December 2, 2025, bringing deep expertise in interventional cardiology that is expected to drive innovation and market expansion in cardiovascular disease treatment.
- Rich Leadership Experience: Slosman, who previously served as CEO of InspireMD and held senior commercial leadership roles at Johnson & Johnson, GE Healthcare, and Baxter International, brings extensive market development and product commercialization experience that will aid BioCardia's strategic growth.
- Gratitude to Former Director: BioCardia expressed appreciation for departing board member Richard Krasno, who provided guidance during key milestones, particularly in the FDA approval of the CardiAMP cell therapy and the Morph DNA product.
- Strategic Company Development: The appointment of Slosman is expected to significantly support BioCardia's clinical value creation and global market expansion, further advancing the company's innovative solutions for treating cardiovascular and pulmonary diseases.
See More
BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality
New Appointment: BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, bringing over 25 years of experience in quality management and regulatory affairs from various companies in the healthcare sector.
Previous Experience: Shahab's prior roles include Vice President of Quality and Regulatory at Welldoc, Senior Director at Intuity Medical, and Director at Moximed, showcasing a strong background in product quality management across multiple medical device categories.
CEO's Statement: Peter Altman, CEO of BioCardia, expressed confidence in Shahab's expertise, stating that his leadership and experience will enhance the company's ability to commercialize investigational products.
Company Overview: BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with ongoing development of clinical-stage product candidates and innovative biotherapeutic delivery platforms.
See More
BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations
Earnings Performance: BioCardia, Inc. reported a loss of $1.48 million for the third quarter, an improvement from a loss of $1.74 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.24, compared to -$0.61 in the previous year, beating analysts' expectations of -$0.25 per share.
See More
